| pubmed-article:7840552 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7840552 | lifeskim:mentions | umls-concept:C0026926 | lld:lifeskim |
| pubmed-article:7840552 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:7840552 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:7840552 | lifeskim:mentions | umls-concept:C0124728 | lld:lifeskim |
| pubmed-article:7840552 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:7840552 | lifeskim:mentions | umls-concept:C0753448 | lld:lifeskim |
| pubmed-article:7840552 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:7840552 | pubmed:dateCreated | 1995-3-2 | lld:pubmed |
| pubmed-article:7840552 | pubmed:abstractText | The activity of KRM-1648 was evaluated in a murine model of tuberculosis. Approximately 10(7) viable Mycobacterium tuberculosis ATCC 35801 organisms were given intravenously to 4-week-old female outbred mice. Treatment was started 1 week postinfection and given by gavage for 4 weeks. Viable-cell counts were determined from homogenates of spleen and lung tissues. The activity of KRM-1648 was compared with those of rifampin and rifabutin at 20 mg/kg of body weight. KRM-1648 was more active than either rifampin or rifabutin against organisms in spleens and lungs. KRM-1648 alone and in combination with either isoniazid, ethambutol, pyrazinamide, or levofloxacin was evaluated. Other treatment groups received isoniazid, ethambutol, pyrazinamide, or levofloxacin as single agents. KRM-1648 was the most active single agent evaluated. KRM-1648-pyrazinamide and KRM-1648-isoniazid were the most active combinations. These combinations were more active than KRM-1648 alone. The promising activity of KRM-1648 in M. tuberculosis-infected mice suggests that it is a good candidate for clinical development as a new antituberculosis agent. | lld:pubmed |
| pubmed-article:7840552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7840552 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7840552 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7840552 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:7840552 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:7840552 | pubmed:author | pubmed-author:CynamonM HMH | lld:pubmed |
| pubmed-article:7840552 | pubmed:author | pubmed-author:KlemensS PSP | lld:pubmed |
| pubmed-article:7840552 | pubmed:author | pubmed-author:GrossiM AMA | lld:pubmed |
| pubmed-article:7840552 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7840552 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:7840552 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7840552 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7840552 | pubmed:pagination | 2245-8 | lld:pubmed |
| pubmed-article:7840552 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:meshHeading | pubmed-meshheading:7840552-... | lld:pubmed |
| pubmed-article:7840552 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7840552 | pubmed:articleTitle | Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. | lld:pubmed |
| pubmed-article:7840552 | pubmed:affiliation | SUNY Health Science Center, Syracuse 13210. | lld:pubmed |
| pubmed-article:7840552 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7840552 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7840552 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7840552 | lld:pubmed |
